Patent · US Active

Anti-CCL17 antibodies

US10829549B2 · kind B2 · utility

1Cited by
23References
7Claims
0Family size

Assignee

Inventors

Key dates

Filing dateDec 8, 2017
Grant dateNov 10, 2020
Priority date
Expiry dateDec 8, 2037

Classification

  • Technology area (CPC Y)Emerging Cross-Sectional Technologies
  • CPC primaryY02A50/30
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention relates to antibodies specifically binding CCL17, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.